Life Science & Pharmaceutical Industry
Patients are taking a more active and demanding role in their own healthcare, which is accelerating the transformation from disease treatment to predictive, personalised, preventive and participatory health solutions.
These, in turn, call for better understanding of patients, tailor-made support and more effective care – for dementia, diabetes and other chronic illnesses.
For pharmaceutical companies, this requires a radical change. Big Data, the digitalisation of medicine and digital health technology are all catalysts for that change. They can get novel, more effective therapies to market faster, be patient-centred and at a lower cost. With expertise in all these fields, Zühlke creates outstanding digital patient experiences and empowers pharmaceutical companies to take a data-driven approach to diagnostics, therapy management and delivery devices.
Upgrading Tech for Personalised Medication and Diagnostics
With a direct line to our households and an unprecedented volume of our personal data, Big Tech businesses represent a big challenge to conventional healthcare companies. Changing expectations exacerbate this situation. Like society as a whole, patients and insurers now expect more individualised health advice and treatment, complementary digital care services, and value-based pricing models. It follows that the digital healthcare market will belong to those companies that successfully combine pharmaceutical know-how and patient centricity with HealthTech and trustworthy data handling.
Zühlke develops medical grade apps and devices that get medication and diagnostics fit for the future of personalised healthcare. We offer extensive experience of developing large-scale B2C platforms combined with 50 years of medical-grade expertise. With us at your side, you can gain – and maintain – leadership of your digitalised industry.
Secure Digital Solutions Build Patient Trust
Machine learning technologies analyze big healthcare data including omics and real-world patient data to help the pharmaceutical industry speed up processes and create new products and services.
Zühlke experts develop secure digital platforms that offer the industry legitimate access to the required large and meaningful volume of anonymous health data. We create positive digital experiences for patients – not least by putting them in control of their data – which helps build trust in pharmaceutical companies. Our approach combines behavioural science, user-centric healthcare apps for patients and cutting-edge technology like federated learning with superior data security.
Connecting Pharma with Ecosystem Innovation
Digital technology innovation is already having a profound impact on Pharma’s whole value chain – from AI-led clinical research and trial design, to a rapidly accelerating ecosystem of digital-first therapies, devices, platforms, and data.
ePaper - 6 Principles powering Digital Health and the patient journey evolution
Pharma-tech frontrunners are using a new model for digital change. We call it Ecosystem Innovation – get started with our ePaper.
Digital Therapeutics with Software as a Medical Device
Even well-established medical treatments can have serious side effects, and put a considerable burden on patients. Digital therapeutics have huge potential to meet these unmet medical needs and challenges – for example in treating mental diseases.
We can design, develop and run your digital therapeutics idea. Our software as a medical device (SaMD) solutions support – or even replace – existing diagnostics and therapies. For pharma companies, this opens up new customer segments as well as business and revenue models that are highly scalable. Compared to traditional treatments, digital therapeutics are faster and easier to distribute worldwide. We help you access this new market by developing patient-centric mobile apps that are safe and compliant with high medical standards such as IEC 62366.
Measure Patient Outcomes with Smart Connected Sensors
For pharmaceutical innovators, it is no longer enough to present study results that prove the efficacy of a new drug. You must provide irrefutable evidence that demonstrates tangible added value compared to established therapies. In line with value-based reimbursement models, this means measuring patient outcomes in real time.
Zühlke helps you do just that, for example by developing the smart connected sensors you need to collect digital biomarker data. Our solutions conform to strict procedural standards and design control. We build and run production-scale data platforms, and use machine learning to generate valuable information from the data we collect. User-friendly apps make it easy to collect the patient reported outcomes (PRO) required to complete the data sets.
Accelerate Clinical Trials with Reliable and Secure Technologies
Clinical trials account for up to 50% of R&D spending in the pharmaceutical industry. Complicated enrolment processes and high dropout rates render them inefficient and time-consuming. Digital technologies can help identify the right cohorts and make it easier for subjects to participate – minimising dropout rates and reducing cost.
Our appealing mobile applications, voice assistances and user-friendly portals improve participants’ trial experience, bringing them closer to you – and you closer to the healthcare provider. We apply our AI expertise to generate valuable insights, and the highest security standards to help establish lasting patient trust in your brand.
Philipp Harrschar is Executive Director Business Development and Partner of the Zühlke Group. He has been with Zühlke since 2011 and provides strategic advice and support to clients in innovation and digitalisation projects. His focus is on cross-sector innovation patterns and the use of key technologies.
Albert Frömel is responsible for the Healthcare & Life Sciences sector in Austria He draws on years of experience with leading national and international health institutions. In doing so, he actively helped shape the solution to the most important digital challenges. His focus is on digital transformation, new intelligence systems and data-driven ecosystems. Together with his team, he empowers his clients to improve patient health outcomes, modernize work environments and ensure future-proof business models. Albert Frömel completes his technical education with a degree from the Vienna University of Economics and Business Administration and regularly gives lectures at conferences.
Nicolas oversees the Healthcare and MedTech vertical at Zuhlke Singapore. As part of the Business Development team, he works on digital innovation initiatives together with both global and local customers. Nicolas finds joy in helping clients connect the dots, from conceptualisation to creation of exciting products.
Bardia M. Zanganeh
Bardia M. Zanganeh is responsible for the Life Sciences and Healthcare practice in Switzerland. He serves leading healthcare institutions on all technology agenda issues. His primary areas of focus include digital innovation, business model transformation and product innovation. He also serves providers as well as medical technology and pharmaceutical companies. He has a background in engineering, consulting and entrepreneurship and is a lecturer at the University of Applied Sciences in Business Administration in Zurich.
Julie Pourtois joined Zuhlke in 2020, heading the Business Development team in Hong Kong. Bringing with her over 15 years of experience in the tech industry, Julie oversees Zuhlke’s market positioning and customer portfolio across regional markets and industries in Asia. Julie strives to positively impact and uplift organisations, teams, and the larger communities she engages actively with.
Whitepaper: Automation of the production of bioengineered skin
The Swiss start-up company Cutiss had an ingenious idea: customised artificial skin for burns victims. In our 12-page whitepaper we describe in detail the processes that led to an effective and successful solution: An automated closed system.
Whitepaper - How to build medical AI
Combining best practices from machine learning and medical device development: Our 17-page whitepaper explores best practices and regulatory requirements for AI in diagnostics.